Ebola Vaccine Immune Correlates and Mechanism of Protection
$1,152,389ZIAFY2009AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 33790899Paper 22560007Paper 21857654Paper 21325402Paper 21228243Paper 21034824Paper 20660192Paper 20502688Paper 20304456Paper 19369954Paper 17238286Paper 16988008Paper 16683867Paper 15937495Paper 15596847
Abstract
Use of the FDA Animal Rule for licensure of Ebola and Marburg virus vaccines requires a detailed understanding of vaccine-induced immune response since correlates of immunity will replace efficacy studies that would otherwise be provided to support vaccine licensure. An immune correlate of protection against infection must first be identified in an animal model that reasonably represents disease pathogenesis in humans. Vaccine efficacy is tested in animals, and the immune response that correlates best with survival is identified. Subsequent immunogenicity studies in human subjects are designed to test whether the vaccine can induce similar responses in humans.
View original record on NIH RePORTER →